Arrowhead Research | ARWR - Current Liabilities


Arrowhead Research reported $311.34M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Moderna USD 2.03B 506M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 32.52B 777M Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
TG Therapeutics USD 260.53M 7.97M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026
Xencor USD 76.27M 5.6M Sep/2026